Supplementary Figures from Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival

<p>Supplementary Figure 1. Relative abundance of glycochenodeoxycholate (GCDC) in human breast tumors and adjacent non-cancerous tissues. Supplementary Figure 2. Association of fatty acid metabolism-related metabolites with breast cancer survival. Supplementary Figure 3. Correlation matrix for bile acids in the Tang et al. breast cancer dataset ("Duke cohort") and association of glycochenodeoxycholate (GCDC) with tumor subtype and proliferation. Supplementary Figure 4. Inverse association between bile acid levels and the tumor proliferation score. Supplementary Figure 5. Tissue glycochenodeoxycholate (GCDC) levels in tumor-adjacent non-cancerous tissue (n = 65) do not associate with the tissue proliferation score. Supplementary Figure 6. Proteomics identifies the Complement & Coagulation pathway as being activated in breast tumors with high glycochenodeoxycholate (GCDC). Supplementary Figure 7. Up-regulated proteins of the Complement & Coagulation Cascade in glycochenodeoxycholate (GCDC)-high tumors. Supplementary Figure 8. TGR5 and OATP1B1/3 antagonists attenuate the anti-proliferative effect of deoxycholate (DC) in T47D cells. Supplementary Figure 9. Up-regulated genes in the Steroid Biosynthesis pathway in deoxycholate-treated T47D cells. Supplementary Figure 10. Differentially expressed genes in the Steroid Hormone Biosynthesis pathway in deoxycholate-treated T47D cells.</p>